153 related articles for article (PubMed ID: 17523051)
1. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1.
Nakagomi-Hagihara R; Nakai D; Tokui T; Abe T; Ikeda T
Xenobiotica; 2007 May; 37(5):474-86. PubMed ID: 17523051
[TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
Shitara Y; Hirano M; Sato H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
[TBL] [Abstract][Full Text] [Related]
3. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans.
Nakagomi-Hagihara R; Nakai D; Tokui T
Xenobiotica; 2007 Apr; 37(4):416-26. PubMed ID: 17455113
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide.
Kimoto E; Li R; Scialis RJ; Lai Y; Varma MV
Mol Pharm; 2015 Nov; 12(11):3943-52. PubMed ID: 26378985
[TBL] [Abstract][Full Text] [Related]
6. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
Yamazaki M; Li B; Louie SW; Pudvah NT; Stocco R; Wong W; Abramovitz M; Demartis A; Laufer R; Hochman JH; Prueksaritanont T; Lin JH
Xenobiotica; 2005 Jul; 35(7):737-53. PubMed ID: 16316932
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
Varma MV; Lin J; Bi YA; Kimoto E; Rodrigues AD
Drug Metab Dispos; 2015 Jul; 43(7):1108-18. PubMed ID: 25941268
[TBL] [Abstract][Full Text] [Related]
8. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
Nakagomi-Hagihara R; Nakai D; Kawai K; Yoshigae Y; Tokui T; Abe T; Ikeda T
Drug Metab Dispos; 2006 May; 34(5):862-9. PubMed ID: 16501004
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
[TBL] [Abstract][Full Text] [Related]
10. Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.
Sharma P; Holmes VE; Elsby R; Lambert C; Surry D
Xenobiotica; 2010 Jan; 40(1):24-37. PubMed ID: 19919292
[TBL] [Abstract][Full Text] [Related]
11. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
12. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
13. Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4.
Hirouchi M; Kusuhara H; Onuki R; Ogilvie BW; Parkinson A; Sugiyama Y
Drug Metab Dispos; 2009 Oct; 37(10):2103-11. PubMed ID: 19628752
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.
Sharma P; Butters CJ; Smith V; Elsby R; Surry D
Eur J Pharm Sci; 2012 Aug; 47(1):244-55. PubMed ID: 22538052
[TBL] [Abstract][Full Text] [Related]
15. Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake of Glucuronide Metabolites of Androgens.
Li CY; Gupta A; Gáborik Z; Kis E; Prasad B
Mol Pharmacol; 2020 Sep; 98(3):234-242. PubMed ID: 32587096
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
17. The new acyl-CoA cholesterol acyltransferase inhibitor SMP-797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems.
Kitamura A; Imai S; Yabuki M; Komuro S
Biopharm Drug Dispos; 2007 Dec; 28(9):517-25. PubMed ID: 17918775
[TBL] [Abstract][Full Text] [Related]
18. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.
Nakai D; Nakagomi R; Furuta Y; Tokui T; Abe T; Ikeda T; Nishimura K
J Pharmacol Exp Ther; 2001 Jun; 297(3):861-7. PubMed ID: 11356905
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Varma MV; Lai Y; Feng B; Litchfield J; Goosen TC; Bergman A
Pharm Res; 2012 Oct; 29(10):2860-73. PubMed ID: 22638872
[TBL] [Abstract][Full Text] [Related]
20. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
